ANO1 and prostate carcinoma: Its overexpression in various cancers, particularly prostate cancer, along with its potential to influence signaling pathways relevant to metastasis, positions TMEM16A as an attractive target for therapeutic intervention and a subject for further research to understand its contributions to cancer progression.